KARUNA KONERU
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- PAOLI, IN
- NPI
- 1336146372
- Received
- $1,284 in 62 records, 2019 to 2024
- As principal investigator
- $27,465 of research payments to others in 6 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 20 | $503 |
| 2023 | General payment | 31 | $594 |
| 2022 | General payment | 4 | $84 |
| 2021 | General payment | 2 | $30 |
| 2020 | General payment | 2 | $28 |
| 2019 | General payment | 3 | $41 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $227 | 2022–2024 |
| AstraZeneca Pharmaceuticals LP | 7 | $141 | 2020–2023 |
| Merck Sharp & Dohme LLC | 7 | $132 | 2023–2024 |
| Daiichi Sankyo Inc. | 1 | $108 | 2024 |
| BeiGene USA, Inc. | 1 | $97 | 2024 |
| GENZYME CORPORATION | 4 | $91 | 2023–2024 |
| Celgene Corporation | 4 | $72 | 2022–2023 |
| Eisai Inc. | 3 | $62 | 2023–2024 |
| PFIZER INC. | 3 | $50 | 2023 |
| GlaxoSmithKline, LLC. | 3 | $42 | 2023 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 | 2023 |
| Exelixis Inc. | 2 | $35 | 2022–2023 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 | 2023 |
| Genentech USA, Inc. | 2 | $30 | 2019–2023 |
| ABBVIE INC. | 1 | $29 | 2023 |
| Gilead Sciences, Inc. | 2 | $27 | 2021–2023 |
| Alexion Pharmaceuticals, Inc. | 1 | $19 | 2023 |
| Genmab U.S., Inc. | 1 | $19 | 2024 |
| Janssen Biotech, Inc. | 1 | $14 | 2019 |
| Amgen Inc. | 1 | $11 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 60 | $1,253 |
| Education | 2 | $30 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-05 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-25 | Eisai Inc. | $20 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-11-11 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-11-11 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-11-07 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-10-21 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2024 | |
| 2024-07-15 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-15 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-05-15 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-04-22 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | MEKINIST Drug, Oncology | 2024 | |
| 2024-03-21 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-03-12 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-03-07 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-02-24 | BeiGene USA, Inc. | $97 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2024 | |
| 2024-02-15 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-02-08 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-02-08 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-01-29 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | TAFINLAR Drug, Oncology | 2024 | |
| 2024-01-18 | Daiichi Sankyo Inc. | $108 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-01-15 | Genmab U.S., Inc. | $19 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2024 | |
| 2023-12-18 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-12-11 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-12-07 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Alecensa Biological, BioOncology | 2023 | |
| 2023-11-30 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2023 | |
| 2023-11-27 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | JEVTANA Drug, Oncology | 2023 | |
| 2023-11-13 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-06 | Gilead Sciences, Inc. | $15 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-30 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2023 | |
| 2023-10-23 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | PIQRAY Drug, Oncology | 2023 | |
| 2023-10-19 | Regeneron Healthcare Solutions, Inc. | $18 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-10-11 | Merck Sharp & Dohme LLC | $22 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-10 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-10-05 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-09-25 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2023 | |
| 2023-09-06 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | Pomalyst Drug, Hematology | 2023 | |
| 2023-08-24 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-08-21 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2023 | |
| 2023-08-03 | Eisai Inc. | $20 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-06-19 | Alexion Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2023 | |
| 2023-06-01 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2023-05-31 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2023 | |
| 2023-05-19 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2023 | |
| 2023-05-19 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2023 | |
| 2023-04-10 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2023 | |
| 2023-03-21 | Eisai Inc. | $21 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-02-13 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | JEVTANA Drug, Oncology | 2023 | |
| 2023-02-10 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2023 | |
| 2023-02-02 | Exelixis Inc. | $17 | Food and Beverage | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-01-23 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-20 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2023 | |
| 2023-01-05 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2022-12-13 | Exelixis Inc. | $18 | Food and Beverage | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-12-08 | Celgene Corporation | $12 | Food and Beverage | Cash or cash equivalent | Pomalyst Drug, Hematology | 2022 | |
| 2022-11-01 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | PROMACTA Drug, ONCOLOGY | 2022 | |
| 2022-09-27 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2021-10-08 | AstraZeneca Pharmaceuticals LP | $19 | Education | In-kind items and services | 2021 | ||
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2020-11-04 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2020 | |
| 2020-01-06 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2020 | ||
| 2019-12-18 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | MVASI Biological, Oncology | 2019 | |
| 2019-11-21 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | Balversa Drug, Oncology | 2019 | |
| 2019-07-18 | Genentech USA, Inc. | $15 | Food and Beverage | In-kind items and services | TECENTRIQ Biological, BioOncology | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2020-10-28 | Dova Pharmaceuticals | INDIANA UNIVERSITY HEALTH | $2,250 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-10-28 | Dova Pharmaceuticals | INDIANA UNIVERSITY HEALTH | $3,000 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2020 |
| 2020-07-31 | Amgen Inc. | INDIANA UNIVERSITY HEALTH SOUTHERN INDIANA PHYSICIANS | $255 | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-03-20 | Amgen Inc. | INDIANA UNIVERSITY HEALTH BLOOMINGTON INC | $11,503 | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2019-12-17 | Dova Pharmaceuticals | INDIANA UNIVERSITY HEALTH | $8,750 | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-08-07 | Amgen Inc. | INDIANA UNIVERSITY HEALTH BLOOMINGTON INC | $1,707 | Prospective Observational Study of Onpro vs SOC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Paoli, IN, county Orange County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Paoli, IN | County Orange County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 3,125 | 19,767 | 6,851,073 |
| Population, 2020 census P1 | 3,666 | 19,867 | 6,785,528 |
| Median age B01002 | 42.6 | 42.7 | 38.1 |
| Under 18 B01001 | 23.2% | 22.9% | 23.3% |
| 65 and over B01001 | 31.3% | 20.8% | 16.8% |
| Households B11001 | 1,287 | 7,970 | 2,716,009 |
| Foreign born B05002 | 1.0% | 1.5% | 6.3% |
| Median household income B19013 | $42,906 | $65,873 | $71,957 |
| Median family income B19113 | $51,917 | $85,650 | $90,767 |
| Per capita income B19301 | $31,494 | $34,262 | $38,351 |
| Poverty rate B17001 | 25.2% | 13.4% | 12.3% |
| Unemployment rate B23025 | 7.8% | 3.1% | 4.3% |
| Civilian labor force B23025 | 1,104 | 9,695 | 3,472,016 |
| Mean commute (minutes) B08013 | 24.9 | 25.3 | 24.1 |
| Bachelor's degree or higher B15003 | 14.0% | 16.1% | 29.5% |
| Housing units B25001 | 1,480 | 9,101 | 2,976,568 |
| Owner-occupied B25003 | 62.2% | 78.7% | 70.6% |
| Renters B25003 | 37.8% | 21.3% | 29.4% |
| Median home value B25077 | $150,700 | $158,700 | $218,200 |
| Median gross rent B25064 | $799 | $855 | $1,062 |
| White, not Hispanic B03002 | 86.3% | 93.3% | 75.4% |
| Black B03002 | 0.4% | 1.2% | 9.1% |
| Hispanic or Latino B03002 | 4.4% | 1.8% | 8.6% |
| Asian B03002 | 0.0% | 0.5% | 2.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Paoli, IN.
Comments